Creation of a Clinical Database on Primary Nervous System Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

data collection: Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death

Study summary

the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on:

* The clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of Primary central nervous system tumors (PCNST). This is particularly important for rare histological subtypes of PCNST for which the current knowledge is scarce;
* Clinical, radiological and biological factors predictive of tumor response to treatments;
* Prognostic factors.

Eligibility

Primary outcome measure(s)

• Establish an exhaustive database of patients treated for a Primary central nervous system tumors at the Montpellier Cancer Institute, whatever the histological subtype and the oncological treatment — From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
  collection of clinical data in the medical record

Trial sites (1)

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France